Opus Genetics (IRD) Operating Leases (2019 - 2020)
Opus Genetics (IRD) posted quarterly Operating Leases of $25790.0 for Q1 2020, down 85.79% year-over-year from $181490.0 in Q2 2019, and down 59.45% quarter-over-quarter from $63605.0 in Q4 2019.
Powered by 
Analysis
Opus Genetics (IRD) Operating Leases (2019 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Operating Leases for 2 consecutive years, with $25790.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Operating Leases fell 85.79% year-over-year to $25790.0; the TTM figure through Mar 2020 stood at $25790.0 (down 85.79% YoY), while the FY2019 annual figure was $63605.0, changed N/A from the prior year.
- Operating Leases declined to $25790.0 in Q1 2020 per IRD's latest filing, from $63605.0 in the prior quarter.
- Across five years, Operating Leases topped out at $181490.0 in Q1 2019 and bottomed at $25790.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 25,790.00 |
| Dec 31, 2019 | 63,605.00 |
| Sep 30, 2019 | 100,397.00 |
| Jun 30, 2019 | 136,196.00 |
| Mar 31, 2019 | 181,490.00 |